Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
ArrowMark Partners
AddedFeb 11, 2024
UpdatedJun 28, 2026
ArrowMark Partners

ArrowMark Partners

Operating

ArrowMark Partners: An employee-owned firm managing $19.5B in assets across diverse strategies since 2007.

Location
Denver, CO, US
Founded
2007
Firm
Compare
Portfolio
Employees
News
Website

Investments

SmartLabs
SmartLabs

Total Raised

$402.6M

Rounds

6

Series C$48MJanuary 2024
Series B$250MSeptember 2021
Arvinas
Arvinas
Public

Total Raised

$461.6M

Rounds

5

Post Ipo Equity$350MNovember 2023
Beta Bionics
Beta Bionics

Total Raised

$293.5M

Rounds

8

Series D$100MAugust 2023
Series C$57MFebruary 2022
Checkerspot
Checkerspot

Total Raised

$109M

Rounds

5

Series C$55MFebruary 2023
Sonendo
Sonendo
Public

Total Raised

$334.7M

Rounds

15

Post Ipo Equity$63MSeptember 2022
Aktis Oncology
Aktis Oncology

Total Raised

$156M

Rounds

2

Series A$84MAugust 2022
Dren Bio
Dren Bio

Total Raised

$130.1M

Rounds

4

Series B$65MJune 2022
Simcha Therapeutics
Simcha Therapeutics

Total Raised

$65M

Rounds

2

Series B$40MJanuary 2022
Big Health
Big Health

Total Raised

$129.3M

Rounds

4

Series C$75MJanuary 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Arbor Biotechnologies
Arbor Biotechnologies

Total Raised

$230.6M

Rounds

2

Series B$215MNovember 2021
Fyllo
Fyllo

Total Raised

$101.1M

Rounds

6

Series C$40MNovember 2021
Skyryse
Skyryse

Total Raised

$240.5M

Rounds

5

Series B$200MOctober 2021
TrialSpark
TrialSpark

Total Raised

$156M

Rounds

3

Series C$156MSeptember 2021
Ginkgo Bioworks
Ginkgo Bioworks
Public

Total Raised

$1.6B

Rounds

17

Post Ipo Equity$775MSeptember 2021
Sonoma Biotherapeutics
Sonoma Biotherapeutics

Total Raised

$365M

Rounds

4

Series B$265MAugust 2021
Frontier Medicines
Frontier Medicines

Total Raised

$244M

Rounds

3

Series B$88.5MJuly 2021
Tvardi Therapeutics
Tvardi Therapeutics

Total Raised

$81.4M

Rounds

2

Series B$72.4MJune 2021
Latch
Latch
Acquired

Total Raised

$342.1M

Rounds

8

Post Ipo Equity$190MJune 2021
Absci
Absci
Public

Total Raised

$237.9M

Rounds

11

Series Unknown$125MMarch 2021
Dataminr
Dataminr

Total Raised

$1.1B

Rounds

12

Series F$475MMarch 2021
Neurogene
Neurogene
Public

Total Raised

$183.5M

Rounds

3

Series B$115MDecember 2020
Adagio Medical
Adagio Medical

Total Raised

$65.6M

Rounds

6

Series E$42.5MNovember 2020